Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Vistin Pharma ASA : Key information for the subsequent repair issue

Vistin Pharma ASA
Posted on: 22 Mar 18
Reference is made to the stock exchange notice from Vistin Pharma ASA earlier today, 22 March 2018, regarding a subsequent repair issue of approximately NOK 50 million. Key information for the subsequent repair issue is described below.   ---   Date on which the terms and conditions of the subsequent repair issue were announced: 22 March 2018   Last day including right: 22 March 2018   Ex-date: 23 March 2018   Record Date: 26 March 2018   Date of approval: 9 May 2018   Maximum number of new shares: 4,464,286   Subscription price: NOK 11.20   Will the rights be listed - yes/no: No   Other information: The subsequent repair issue is subject to approval by the annual general meeting of Vistin Pharma ASA and approval and publication of a prospectus, expected to take place on or about 11 May 2018.   This information is published in accordance with the requirements of the Continuing Obligations.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vistin Pharma ASA via GlobeNewswire

Last updated on: 23/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.